Saideep Healthcare and Research has raised equity
Saideep Healthcare and Research Private Limited has successfully completed a fundraising. This funding will help Saideep become a leading healthcare brand, offering advanced specialties across the region. The funds from this collaboration will be used to diversify into new and complex specialties, expand infrastructure and meet the growing demand for high-quality healthcare services in Western India.
Saideep is a 260-bed multispecialty hospital based in Ahmednagar, Maharashtra, India, that has redefined healthcare delivery in the region since its inception in February 2019. This institution was founded through a collaborative effort by leading consultants in the city, who combined their expertise and resources to create a state-of-the-art facility.
Oaklins’ team in India advised the client on securing a strategic partner through an equity fundraise, and developed a strategy that led to a highly profitable exit for existing shareholders after four years.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more